The most popular Healio Dermatology stories of the past week cover topics across the board: a toxicology study on sunscreen ingredients, clinical trial results from a bactericidal, antibiotic gel for acne and brodalumab use in psoriasis for patients of different ethnic backgrounds.
In the most popular study on sunscreen toxicity, all four sunscreens tested resulted in avobenzone exposures. The three products with oxybenzone resulted in oxybenzone exposure and plasma concentration exceeding 20 ng/mL on day 7.
More data needed on plasma concentrations of sunscreen ingredients
When sunscreens were used under maximal use conditions, plasma concentrations exceeded the threshold established by the FDA for waiving some nonclinical toxicology studies for sunscreens, according to data published in JAMA. Read more.
Bactericidal, antibiotic acne topical treatment reduces inflammatory lesions
Vyome Therapeutics reported results from two clinical trials of its anti-acne candidate VB-1953; the bactericidal, antibiotic topical gel kills sensitive and resistant strains of Propionibacterium acnes infection, and has been shown to reduce inflammation, at the Society for Investigative Dermatology annual meeting in Chicago. Read more.
Brodalumab viable option for psoriasis across racial, ethnic subgroups
Brodalumab was associated with skin clearance in the treatment of moderate to severe plaque psoriasis across various subgroups defined by race or ethnicity, according to a study. Read more.